Sustained intra-articular release of celecoxib from in situ forming gels made of acetyl-capped PCLA-PEG-PCLA triblock copolymers in horses

Biomaterials

Volumn 53, Issue , 2015, Pages 426-436

  Petit, Audrey ^a,b   Redout, Everaldo M ^c   van de Lest, Chris H ^c   de Grauw, Janny C ^c   Müller, Benno ^a   Meyboom, Ronald ^a   van Midwoud, Paul ^a   Vermonden, Tina ^b   Hennink, Wim E ^b   Rene van Weeren P ^c  

^a InGell Labs BV   (Netherlands)

^b UTRECHT UNIVERSITY   (Netherlands)

^c UTRECHT UNIVERSITY   (Netherlands)

Author keywords

Celecoxib; Histology; Hyaluronic acid; Hydrogel; Intra articular delivery; Local delivery

Indexed keywords

GELS; HISTOLOGY; HYALURONIC ACID; HYDROGELS; JOINTS (ANATOMY); ORGANIC ACIDS; POLYETHYLENE GLYCOLS; POLYETHYLENE OXIDES; TARGETED DRUG DELIVERY;

CELECOXIB; DETECTION LIMITS; IN-SITU FORMING GELS; INFLAMMATORY RESPONSE; INTRA-ARTICULAR DELIVERY; INTRA-ARTICULAR INJECTION; LOCAL DELIVERY; SUSTAINED RELEASE;

CONTROLLED DRUG DELIVERY;

CELECOXIB; COPOLYMER; HYALURONIC ACID; MACROGOL; POLY(EPSILON CAPROLACTONE C LACTIDE); POLYCAPROLACTONE; UNCLASSIFIED DRUG; CYCLOOXYGENASE 2 INHIBITOR; DRUG CARRIER; GEL; MACROGOL DERIVATIVE; POLY(EPSILON-CAPROLACTONE-CO-LACTIDE)-POLY(ETHYLENE GLYCOL); POLYESTER;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; ARTICULAR CARTILAGE; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG RELEASE; GEL; HORSE; NONHUMAN; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; SYNOVIAL FLUID; SYNOVITIS; X RAY DIFFRACTION; ACETYLATION; ANIMAL; CHEMISTRY; JOINT; METABOLISM;

EQUIDAE;

ACETYLATION; ANIMALS; CELECOXIB; CYCLOOXYGENASE 2 INHIBITORS; DRUG CARRIERS; GELS; HORSES; JOINTS; POLYESTERS; POLYETHYLENE GLYCOLS; PROTON MAGNETIC RESONANCE SPECTROSCOPY; SYNOVIAL FLUID; X-RAY DIFFRACTION;

EID: 84927926749     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2015.02.109     Document Type: Article

References (54)

1. Odding E., Valkenburg H.A., Stam H.J., Hofman A. Determinants of locomotor disability in people aged 55 years and over: the Rotterdam study. Eur J Epidemiol 2001, 17:1033-1041.
2. Suri P., Morgenroth D.C., Hunter D.J. Epidemiology of osteoarthritis and associated comorbidities. PMR 2012, 4:S10-S19.
3. van Weeren P.R., de Grauw J.C. Pain in osteoarthritis. Vet Clin North Am Equine Pract 2010, 26:619-642.
4. Roth S.H., Anderson S. The NSAID dilemma: managing osteoarthritis in high-risk patients. Phys Sportsmed 2011, 39:62.
5. Mastbergen S.C., Bijlsma J.W., Lafeber F.P. Selective COX-2 inhibition is favorable to human early and late-stage osteoarthritic cartilage: a human invitro study. Osteoarthr Cartil 2005, 13:519-526.
6. Gong L., Thorn C.F., Bertagnolli M.M., Grosser T., Altman R.B., Klein T.E. Celecoxib pathways: pharmacokinetics and pharmacodynamics. Pharmacogenet Genomics 2012, 22:310-318.
7. Brophy J.M. Celecoxib and cardiovascular risks. Expert Opin Drug Saf 2005, 4:1005-1015.
8. Edwards S.H.R. Intra-articular drug delivery: the challenge to extend drug residence time within the joint. Vet J 2011, 190:15-21.
9. Jiang D., Zou J., Huang L., Shi Q., Zhu X., Wang G., et al. Efficacy of intra-articular injection of celecoxib in a rabbit model of osteoarthritis. Int J Mol Sci 2010, 11:4106-4113.
10. Butoescu N., Jordan O., Doelker E. Intra-articular drug delivery systems for the treatment of rheumatic diseases: a review of the factors influencing their performance. Eur J Pharm Biopharm 2009, 73:205-218.
11. Larsen C., Østergaard J., Larsen S.W., Jensen H., Jacobsen S., Lindegaard C., et al. Intra-articular depot formulation principles: role in the management of postoperative pain and arthritic disorders. JPharm Sci 2008, 97:4622-4654.
12. Gerwin N., Hops C., Lucke A. Intra-articular drug delivery in osteoarthritis. Adv Drug Deliv Rev 2006, 58:226-242.
13. Hameed F., Ihm J. Injectable medications for osteoarthritis. PM R 2012, 4:S75-S81.
14. Xavier A. Injections in the treatment of osteoarthritis. Best Pract Res Cl Rh 2001, 15:609-626.
15. Chan A., Orme R.P., Fricker R.A., Roach P. Remote and local control of stimuli responsive materials for therapeutic applications. Adv Drug Deliv Rev 2013, 65:497-514.
16. Ko D.Y., Shinde U.P., Yeon B., Jeong B. Recent progress of in situ formed gels for biomedical applications. Prog Polym Sci 2013, 38:672-701.
17. Wolinsky J.B., Colson Y.L., Grinstaff M.W. Local drug delivery strategies for cancer treatment: gels, nanoparticles, polymeric films, rods, and wafers. JControl Release 2012, 159:14-26.
18. Vermonden T., Censi R., Hennink W.E. Hydrogels for protein delivery. Chem Rev 2012, 112:2853-2888.
19. Bonacucina G., Cespi M., Mencarelli G., Giorgioni G., Palmieri G.F. Thermosensitive self-assembling block copolymers as drug delivery systems. Polymers 2011, 3:779-811.
20. van Tomme S.R., Storm G., Hennink W.E. In situ gelling hydrogels for pharmaceutical and biomedical applications. Int J Pharm 2008, 355:1-18.
21. Petit A., Sandker M., Müller B., Meyboom R., van Midwoud P., Bruin P., et al. Release behavior and intra-articular biocompatibility of celecoxib-loaded acetyl-capped PCLA-PEG-PCLA thermogels. Biomaterials 2014 Sep, 35(27):7919-7928.
22. Zentner G.M., Rathi R., Shih C., McRea J.C., Seo M., Oh H., et al. Biodegradable block copolymers for delivery of proteins and water-insoluble drugs. JControl Release 2001, 72:203-215.
23. Qiao M., Chen D., Ma X., Liu Y. Injectable biodegradable temperature-responsive PLGA-PEG-PLGA copolymers: synthesis and effect of copolymer composition on the drug release from the copolymer-based hydrogels. Int J Pharm 2005, 294:103-112.
24. Gao Y., Ren F., Ding B., Sun N., Liu X., Ding X., et al. Athermo-sensitive PLGA-PEG-PLGA hydrogel for sustained release of docetaxel. JDrug Target 2011, 19:516-527.
25. ®/paclitaxel) - clinical applications for a novel paclitaxel delivery system. Adv Drug Deliv Rev 2009, 61:785-794.
26. Bramfeldt H., Sarazin P., Vermette P. Characterization, degradation, and mechanical strength of poly(D,L-lactide-co-ε-caprolactone)-poly(ethylene glycol)-poly(D,L-lactide-co-ε-caprolactone). JBiomed Mater Res A 2007, 83A:503-511.
27. Zhang Z., Ni J., Chen L., Yu L., Xu J., Ding J. Biodegradable and thermoreversible PCLA-PEG-PCLA hydrogel as a barrier for prevention of post-operative adhesion. Biomaterials 2011, 32:4725-4736.
28. Petit A., Müller B., Meijboom R., Bruin P., van de Manakker F., Versluijs-Helder M., et al. Effect of polymer composition on rheological and degradation properties of temperature-responsive gelling systems composed of acyl-capped PCLA-PEG-PCLA. Biomacromolecules 2013, 14:3172-3182.
29. Petit A., Müller B., Bruin P., Meijboom R., Piest M., Kroon-Batenburg L.M.J., et al. Modulating the rheological and degradation properties of hydrogels composed of blends of PCLA-PEG-PCLA triblock copolymers and their fully hexanoyl-capped derivatives. Acta Biomater 2012, 8:4260-4267.
30. Sandker M.J., Petit A., Redout E.M., Siebelt M., Müller B., Bruin P., et al. In situ forming acyl-capped PCLA-PEG-PCLA triblock copolymer based hydrogels. Biomaterials 2013, 34:8002-8011.
31. Anonymous Guide for veterinary services and judging of equestrian events. Am Assoc Equine Pract 1991, p19. 4th ed.
32. Gregory M.H., Capito N., Kuroki K., Stoker A.M., Cook J.L., Sherman S.L. Areview of translational animal models for knee osteoarthritis. Arthritis 2012, 2012:764621.
33. Goodrich L.R., Nixon A.J. Medical treatment of osteoarthritis in the horse - a review. Vet J 2006, 171:51-69.
34. Peyron J.G. Intraarticular hyaluronan injections in the treatment of osteoarthritis: state-of-the-art review. JRheumatol Suppl 1993, 39:10-15.
35. Colen S., van den Bekerom M.P., Mulier M., Haverkamp D. Hyaluronic acid in the treatment of knee osteoarthritis: a systematic review and meta-analysis with emphasis on the efficacy of different products. BioDrugs 2012, 26:257-268.
36. Trigkilidas D., Anand A. The effectiveness of hyaluronic acid intra-articular injections in managing osteoarthritic knee pain. Ann R Coll Surg Engl 2013, 95:545-551.
37. Brandt K.D., Smith G.N.J., Simon L.S. Intra-articular injection of hyaluronan as treatment for knee osteoarthritis: what is the evidence?. Arthritis Rheum 2000, 43:1192-1203.
38. Reichenbach S., Blank S., Rutjes A.W., Shang A., King E.A., Dieppe P.A., et al. Hylan versus hyaluronic acid for osteoarthritis of the knee: a systematic review and meta-analysis. Arthritis Rheum 2007, 15. 1410-1408.
39. Jo S., Kim J., Kim S.W. Reverse thermal gelation of aliphatically modified biodegradable triblock copolymers. Macromol Biosci 2006, 6:923-928.
40. Bertone A.L., Palmer J.L., Jones J. Synovial fluid cytokines and eicosanoids as markers of joint disease in horses. Vet Surg 2001, 30:528-538.
41. de Grauw J.C., van de Lest C.H., Brama P.A., Rambags B.P., van Weeren P.R. Invivo effects of meloxicam on inflammatory mediators, MMP activity and cartilage biomarkers in equine joints with acute synovitis. Equine Vet J 2009, 41:693-966.
42. de Grauw J.C., van de Lest C.H., van Weeren P.R. Inflammatory mediators and cartilage biomarkers in synovial fluid after a single inflammatory insult: a longitudinal experimental study. Arthritis Res Ther 2009, 11. R35.
43. Zhang Y., Huo M., Zhou J., Xie S. PKSolver: an add-in program for pharmacokinetic and pharmacodynamic data analysis in microsoft Excel. Comput Methods Programs Biomed 2010, 99:306-314.
44. Paulson S.K., Kaprak T.A., Gresk C.J., Fast D.M., Baratta M.T., Burton E.G., et al. Plasma protein binding of celecoxib in mice, rat, rabbit, dog and human. Biopharm Drug Dispos 1999, 20:293-299.
45. van Loon J.P., de Grauw J.C., van Dierendonck M., L'ami J.J., Back W., van Weeren P.R. Intra-articular opioid analgesia is effective in reducing pain and inflammation in an equine LPS induced synovitis model. Equine Vet J 2010, 42:412-419.
46. Zheng X., Baker H., Hancock W.S., Fawaz F., McCaman M., Pungor E.J. Proteomic analysis for the assessment of different lots of fetal bovine serum as a raw material for cell culture. Part IV. Application of proteomics to the manufacture of biological drugs. Biotechnol Prog 2006, 22:1294-1300.
47. Gawlitta D., van Rijen M.H., Schrijver E.J., Alblas J., Dhert W.J. Hypoxia impedes hypertrophic chondrogenesis of human multipotent stromal cells. Tissue Eng Part A 2012, 18(19-20):1957-1966.
48. Larsen S.W., Frost A.B., Østergaard J., Thomsen M.H., Jacobsen S., Skonberg C., et al. Invitro and invivo characteristics of celecoxib in situ formed suspensions for intra-articular administration. JPharm Sci 2011, 100:4330-4337.
49. Hosseininia S., Lindberg L.R., Dahlberg L.E. Cartilage collagen damage in hip osteoarthritis similar to that seen in knee osteoarthritis; a case-control study of relationship between collagen, glycosaminoglycan and cartilage swelling. BMC Musculoskelet Disord 2013, 14:18.
50. Siepmann J., Peppas N.A. Higuchi equation: derivation, applications, use and misuse. Int J Pharm 2011, 418(1):6-12.
51. Szekanecz Z., Koch A. Vascular involvement in rheumatic diseases: 'vascular rheumatology'. Arthritis Res Ther 2008, 10:224.
52. Yehia S.R., Duncan H. Synovial fluid analysis. Clin Orthop Relat Res 1975, 107:11-24.
53. Gika H.G., Theodoridou A., Michopoulos F., Theodoridis G., Diza E., Settas L., et al. Determination of two COX-2 inhibitors in serum and synovial fluid of patients with inflammatory arthritis by ultra performance liquid chromatography-inductively coupled plasma mass spectroscopy and quadrupole time-of-flight mass spectrometry. JPharm Biomed Anal 2009, 49:579-586.
54. Bhala N., Emberson J., Merhi A., Abramson S., Arber N., Baron J.A., et al. Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. Lancet 2013 Aug 31, 382(9894):769-779. Coxib and traditional NSAID Trialists' (CNT) Collaboration.